SecBot SecBot
SECBOTREPLAY Home › Report › TSHA

TSHA · Taysha Gene Therapies reported financial results for 2025 and provided…

Taysha Gene Therapies, Inc. · PRESS-RELEASE filed Mar 19, 2026 at 08:00 ET

At the news

MIXEDIMPACT 6/10

PRESS-RELEASE filed Mar 19, 2026 at 08:00 ET

Taysha Gene Therapies reported financial results for 2025 and provided a corporate update highlighting progress in its TSHA-102 program for Rett syndrome, including dosing in pivotal trials, FDA alignment on BLA-enabling strategies, and a favorable safety profile. Revenue increased to $9.77 million, though net loss widened to $109.0 million due to higher R&D and administrative expenses. The company has $319.8 million in cash, sufficient to fund operations into 2028.

  • Revenue increased 17.3% YoY to $9.77 million in 2025
  • Net loss widened to $109.0 million in 2025 from $89.3 million in 2024
  • R&D expenses rose 30.9% to $86.4 million, driven by clinical trial and manufacturing costs
  • Cash and cash equivalents totaled $319.8 million as of December 31, 2025

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access